One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.
The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.
A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
The company’s second foray with a PI3K inhibitor shows signs of additive activity, but investors punish it all the same.